Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

Biotechnology

Health Care

Entact Bio

Victoria Richon

Stefanie Schalm

Victor Serebrov

Simon Bushell

Paul Perkins

Owen Smith

Elma Kadic

Bob Soh

The Research and Development team at Entact Bio is focused on exploring and innovating new therapeutic approaches through the design and development of enhancement-targeting chimeric (ENTAC) medicines. Leveraging their expertise in deubiquitinase biochemistry and small-molecule drug development, they work collaboratively to understand protein regulation and create novel treatments that enhance protein function for various diseases.

Research and Development

Biological Sciences Research

Leadership Team

Research and Development

About

Team members

Other teams at Entact Bio

Biological Sciences Research

Leadership Team